Introduction
============

Cancer has become one of the most serious diseases threatening human health. According data from GLOBOCAN 2008, about 12.7 million new cancer cases and 7.6 million cancer deaths have occurred.[@b1-tcrm-11-237] Unfortunately, the mechanisms of cancer still need intensive study. Interactions between genetic and environmental factors were proved to play a dominant role in the occurrence and progression of cancer.[@b2-tcrm-11-237],[@b3-tcrm-11-237] It seems that discovering the effects of genes and the environment on humans would result in a big step being taken toward healing cancer.

Prostate stem cell antigen (*PSCA*) is a prostate-specific gene, which was initially discovered by Reiter et al by representational difference analysis.[@b4-tcrm-11-237] *PSCA* encodes a 123 amino acid cell surface protein with 30% homology to stem cell antigen 2 (SCA-2) that belongs to the Thy-1/Ly-6 family and is located on chromosome 8q24.2. *PSCA* is not only overexpressed in prostate cancer, but was also demonstrated to be highly expressed in other malignancies such as bladder, renal, pancreatic, and ovarian cancers.[@b4-tcrm-11-237]--[@b8-tcrm-11-237] The most extensively studied single nucleotide polymorphism (SNP) in *PSCA* is rs2294008 C \> T. Although in vitro experiments have revealed that the variant rs2294008T could reduce the transcriptional activity of an upstream fragment of *PSCA*, its mechanism and physiological function are still unknown.[@b5-tcrm-11-237],[@b9-tcrm-11-237] Previously, genome-wide association studies (GWAS) have found that the rs2294008 polymorphism in *PSCA* is significantly associated with gastric and bladder cancers. Although several studies have described the relationship between the rs2294008 polymorphism and other cancers, the sample sizes of these studies were small. More recently, five meta-analyses have assessed the relationship between the polymorphism of PSCA rs2294008 C \> T and the susceptibility to gastric cancer.[@b10-tcrm-11-237]--[@b14-tcrm-11-237] However, the results of these meta-analyses were not entirely consistent. Especially the results of subgroup analysis by ethnicity are controversial. Furthermore, there is a lack of evidence of a relationship between the rs2294008 polymorphism and cancer overall. Additionally, the genetic variant of rs2294008 may be correlated with cancer risk in different cancer type and/or ethnicity. Herein, we carried out a meta-analysis to derive a more precise evaluation on the relationship between the rs2294008 polymorphism and cancer risk.

Materials and methods
=====================

Publication search strategy
---------------------------

We searched the databases of PubMed, ISI Web of Knowledge, EMBASE, and Chinese National Knowledge Infrastructure (CNKI) for related articles with the keywords: "*PSCA*/Prostate stem cell antigen", "rs2294008", "single nucleotide polymorphism/SNP/variation/genotype", and "cancer/carcinoma/tumor/neoplasm". The last search was updated on September 30, 2014. All published papers with available full text matching the eligible criteria were retrieved. Furthermore, the references of relevant reviews and eligible articles that our search retrieved were checked.

Inclusion and exclusion criteria
--------------------------------

The following criteria were used to select the eligible literature for this meta-analysis: 1) original papers investigating the associations between *PSCA* (rs2294008) polymorphisms and cancer risk; 2) case--control studies; and 3) full-text published articles and included detailed genotyping data.

Accordingly, the exclusion criteria were: 1) no control group; 2) no available or detailed genotype frequency; and 3) reviews and duplicated studies.

Data extraction and synthesis
-----------------------------

The literature were carefully extracted from all eligible studies independently by two reviewers according to the inclusion and exclusion criteria mentioned above. If these two reviewers could not reach an agreement, another reviewer was consulted to resolve the controversy. The following information were extracted from all included studies: first author, published year, country of origin, cancer type, ethnicity, genotyping methods, source of control, sample size of cases and controls, and the distribution of each genotype in case and control groups. The subgroups grouped according to cancer types included gastric cancer, bladder cancer, and others. With regard to ethnicity, the studies included Caucasian, Asian, and mixed ethnicity (ie, the ethnicity was unclear).

Statistical analysis
--------------------

The associations between the *PSCA* (rs2294008) polymorphism and cancer risk were measured by the odds ratio (OR) with 95% confidence intervals (CIs) according to allele contrast (T vs C), homozygote (TT vs CC), heterozygote (TC vs CC), recessive (TT vs CC + TC), and dominant (CC vs TC + TT) models. The significance of the overall OR was determined by the *Z* test. Heterogeneity among studies was evaluated with the *Q* and *I*^2^ statistic tests. If the *P*-value of the heterogeneity test was greater than 0.05 (*P*\>0.05), the pooled OR estimate of each study was calculated by the fixed effects model. Otherwise, the random effects model was used.[@b15-tcrm-11-237] Furthermore, sources of heterogeneity were investigated by stratified analysis based on cancer type and ethnicity as mentioned above. A funnel plot was used to evaluate publication bias. All statistical analyses were carried out with Review Manager (Revman; v5.2; The Cochrane Collaboration, Oxford, UK).

Results
=======

Characteristics of studies
--------------------------

As shown in [Figure 1](#f1-tcrm-11-237){ref-type="fig"}, a total of 38 potential articles were extracted after the initial search. Fourteen articles were excluded after further screening. Six studies were excluded because they were systematic review articles. One article was excluded because it was not a case--control study. Seven articles were excluded because of a lack of detailed genotyping data. Finally, 26 studies from 24 publications[@b9-tcrm-11-237],[@b16-tcrm-11-237]--[@b38-tcrm-11-237] including 30,050 multiple cancer cases and 51,670 controls were included in this meta-analysis.

The characteristics of the included studies are summarized in [Table 1](#t1-tcrm-11-237){ref-type="table"}. Among the 26 studies, there were 17 studies of gastric cancer, five studies of bladder cancer, two studies of esophageal cancer, two studies of gallbladder cancer, and one study of colorectal cancer. As for subjects, 19 studies had an Asian background, seven studies had a Caucasian background, and only one had a 'mixed' background. Furthermore, there were eleven hospital-based studies and 15 population-based studies.

Quantitative data synthesis
---------------------------

As shown in [Table 2](#t2-tcrm-11-237){ref-type="table"}, the frequency of the minor allele varied widely across the 26 eligible studies, ranging from 0.23 to 0.71. The average frequency of the minor allele in gastric cancer, bladder cancer, and other cancers were 0.45, 0.47, and 0.27, respectively. The average frequency of the T allele was 0.40, 0.49, and 0.63 in Asians, Caucasians, and the mixed group, respectively.

In terms of overall analysis, a significant association was found in all genetic models (T vs C, OR: 1.18, 95% CI: 1.08--1.28, *P*=0.0001; TT vs CC, OR: 1.36, 95% CI: 1.14--1.62, *P*=0.0008; TC vs CC, OR: 1.29, 95% CI: 1.17--1.44, *P*\<0.00001; dominant model TT + TC vs CC, OR: 1.32, 95% CI: 1.18--1.49, *P*\<0.00001; recessive model TT vs TC + CC, OR: 1.15, 95% CI: 1.02--1.30, *P*=0.02).

In subgroup analysis by cancer type, we found that the T allele had a significantly high risk of gastric cancer and bladder cancer, but null association in other cancers ([Table 3](#t3-tcrm-11-237){ref-type="table"}). For gastric cancer, our meta-analysis contained 17 studies with 14,886 cases and 28,782 controls. The rs2294008 polymorphism was associated with gastric cancer risk in four genetic models (T vs C, OR: 1.26, 95% CI: 1.10--1.45, *P*=0.001; TT vs CC, OR: 1.51, 95% CI: 1.10--2.08, *P*=0.01; TC vs CC, OR: 1.39, 95% CI: 1.19--1.63, *P*\<0.0001; TT + TC vs CC, OR: 1.44, 95% CI: 1.19--1.74, *P*=0.0002). However, the recessive model showed that there was no association between rs2294008 and gastric cancer (OR: 1.22, 95% CI: 0.99--1.49, *P*=0.06).

Five studies with 12,397 cases and 19,237 controls were used to evaluate the relationship between the rs2294008 polymorphism and bladder cancer risk. As shown in [Table 3](#t3-tcrm-11-237){ref-type="table"} and [Figure 2](#f2-tcrm-11-237){ref-type="fig"}, there was a significant association between rs2294008 and bladder cancer risk in all genetic models (T vs C, OR: 1.13, 95% CI: 1.06--1.21, *P*=0.0005; TT vs CC, OR: 1.28, 95% CI: 1.20--1.37, *P*\<0.00001; TC vs CC, OR: 1.23, 95% CI: 1.17--1.30, *P*\<0.00001; TT +TC vs CC, OR: 1.25, 95% CI: 1.19--1.31, *P*\<0.00001; TT vs TC + CC, OR: 1.13, 95% CI: 1.07--1.20, *P*\<0.0001).

In the stratified analysis by ethnicity, pooled analysis of Asians showed that the T allele of the *PSCA* rs2294008 polymorphism was associated with increased cancer risk under all genetic models except for the recessive model (T vs C, OR: 1.19, 95% CI: 1.05--1.35, *P*=0.007, [Figure 3](#f3-tcrm-11-237){ref-type="fig"}; TT vs CC, OR: 1.37, 95% CI: 1.03--1.82, *P*=0.03; TC vs CC, OR: 1.36, 95% CI: 1.18--1.57, *P*\<0.0001; TT + TC vs CC, OR: 1.38, 95% CI: 1.17--1.62, *P*=0.0001). *PSCA* rs2294008 showed a significant association among Caucasians based on three models (T vs C, OR: 1.15, 95% CI: 1.04--1.26, *P*=0.004, [Figure 3](#f3-tcrm-11-237){ref-type="fig"}; TT vs CC, OR: 1.32, 95% CI: 1.10--1.59, *P*=0.003; TT vs TC + CC, OR: 1.15, 95% CI: 1.09--1.22, *P*\<0.00001). However, there was no significant association in Caucasians in the other two genetic models (TC vs CC, OR: 1.13, 95% CI: 0.95--1.34; TT + TC vs CC, OR: 1.18, 95% CI: 1.00--1.40).

Tests of heterogeneity
----------------------

The *Q* and *I*^2^ statistic tests were used to evaluate heterogeneity. For the overall studies, there was statistically significant heterogeneity in this meta-analysis (T vs C, *P*\<0.00001, *I*^2^=91%; TT vs CC, *P*\<0.00001, *I*^2^=90%; TC vs CC, *P*\<0.00001, *I*^2^=85%; dominant model TT + TC vs CC, *P*\<0.00001, *I*^2^=90%; recessive model TT vs CC + TC, *P*\<0.00001, *I*^2^=83%). Therefore, we carried on further subgroup analyses by cancer type and ethnicity, respectively. When the *P*-value of the heterogeneity test was more than 0.05 (*P*\>0.05) in the following analyses, a fixed effects model was performed. Otherwise, the random effects model was used (shown in [Table 3](#t3-tcrm-11-237){ref-type="table"}).

Publication bias
----------------

A funnel plot was used performed to evaluate publication bias in this meta-analysis. According to the funnel plot generated for the genetic models, there was an absence of obvious asymmetries for the distributions of ORs from every study ([Figure 4](#f4-tcrm-11-237){ref-type="fig"}). Therefore, the results indicated that publication bias had little effect in this meta-analysis.

Discussion
==========

*PSCA* is a member of the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored surface proteins, comprising three exons and two introns. Proteins in the Thy-1 family and GPI-anchored proteins have been proven to play a role in T cell activation.[@b39-tcrm-11-237] It has been demonstrated to be upregulated in prostate cancer and several other tumors and plays an important role in cell adhesion, proliferation, and survival.[@b11-tcrm-11-237] Recently, many cancer GWAS and replication studies have revealed the relationship between *PSCA* and risk of different cancers. A study performed by Sakamoto et al indicated that the mechanism of *PSCA*-suppressing cancers may be involved in cell proliferation inhibition and/or cell death induction.[@b9-tcrm-11-237] The findings of our meta-analysis may demonstrate that rs2294008 acts as an effect modifier in the development of different cancers. Of course, further biologically functional studies are warranted to verify the molecular mechanisms.

This comprehensive meta-analysis, involving 26 studies from 24 articles with 30,050 multiple cancer cases and 51,671 controls, showed that the rs2294008 polymorphism is significantly associated with overall cancer risk based on all genetic models. Further stratified analyses by cancer type revealed that the polymorphism was associated with an increased risk for gastric and bladder cancer; no association was found with other cancers in all genetic models. Studies from Dai et al[@b16-tcrm-11-237] and Lochhead et al[@b31-tcrm-11-237] indicated that the variant rs2294008C may have a protective role in esophageal cancer, but large well-designed studies are warranted to confirm this conclusion. The stratified analysis by ethnicity showed that the rs2294008 polymorphism was associated with an increased risk of cancer in both Asians and Caucasians. However, there was no study based on patients with an African background. Larger scale multicenter studies based on Africans are warranted to further validate the association between the rs2294008 polymorphism and cancer risk.

So far, there have been five meta-analyses that have investigated the role of the *PSCA* rs2294008 polymorphism in gastric cancer risk.[@b10-tcrm-11-237]--[@b14-tcrm-11-237] All of them had the same finding that the rs2294008 polymorphism is associated with increased risk of gastric cancer. The stratified analyses by ethnicity were performed in four meta-analyses.[@b10-tcrm-11-237]--[@b12-tcrm-11-237],[@b14-tcrm-11-237] Significantly increased risks were found for rs2294008 both among Asians and Caucasians in three articles,[@b10-tcrm-11-237]--[@b12-tcrm-11-237] which is congruous with our results. However, one study showed no significant associations with the rs2294008 polymorphism and Caucasians.[@b14-tcrm-11-237] The latest research in these five published meta-analyses was performed by Gu et al.[@b14-tcrm-11-237] Their last search update was on August 2013, and in total, they identified 16 studies, including 18,820 gastric cases and 35,756 controls for the rs2294008 polymorphism. Compared to these five meta-analyses, we added another nine studies on other cancers in addition to gastric cancer. Our updated meta-analysis extracted data from all the published studies including 26 studies from 24 articles with 30,050 cancer cases and 51,671 controls. This meta-analysis provided evidence on the overall cancer risk of rs2294008 and contained the newest data and largest sample size on the relationship between rs2294008 and cancer. Thus, our results are more comprehensive and persuasive.

Although the pooled analysis was performed to show the association between rs2294008 and cancer risk, some limitations still inevitably exist in this meta-analysis. Firstly, we excluded some studies because of the limits of raw data. Secondly, we could not obtain all articles. Some unpublished literature and relevant published reports in other languages except English and Chinese that may be eligible for this meta-analysis were missed. Thirdly, there were only two studies on esophageal cancer, two on gallbladder cancer, and one on colorectal cancer. Additionally, there was a lack of studies on other types of cancers. Hence, the final OR was largely contributed by the ORs of gastric or bladder cancer; more evidence is needed to prove whether the rs2294008 polymorphism is association with cancer overall. Further large-scale multicenter studies based on a variety of cancer types are needed. Fourthly, the sources of the controls were not consistent. Both population-based healthy individuals and hospital patients without cancer were included in the control groups. Controls enrolled from hospitals may not always truly represent the underlying source populations, especially when the polymorphism was also expected to affect the risk of other diseases. Fifthly, the genotyping methods of the eligible studies were not identical, which may influence the results. Finally, because of the limit of individual data, the ORs of this meta-analysis were not strictly adjusted by the same potential confounders, such as age, sex, and stage of tumor. Additionally, a more precise analysis could be performed to eliminate the confounding bias.

Conclusion
==========

In conclusion, the present meta-analysis demonstrated that the *PSCA* rs2294008 C \> T polymorphism is a risk factor for cancer in both Asians and Caucasians. Furthermore, rs2294008 is associated with an increased risk of gastric and bladder cancer. Further large case--control studies are needed to assess the relationship between rs2294008 and other cancer types.

This study was supported by the National Natural Science Foundation of China (no 81471670, 81472822); the International Cooperative Project of Shaanxi province, China (no 2013KW-32-01); the China Postdoctoral Science Foundation (no 2014M560791); the Fundamental Research Funds for the Central Universities, China (no 2014qngz-04), and the Specialized Research Fund of The Second Affiliated Hospital of Xi'an Jiaotong University, China (RC \[GG\] 201203).

**Disclosure**

The authors report no conflicts of interest in this work.

![Flow chart of study selection.\
**Abbreviation:** CNKI, Chinese National Knowledge Infrastructure.](tcrm-11-237Fig1){#f1-tcrm-11-237}

![Forest plots of the *PSCA* rs2294008 polymorphism and cancer risk in the overall population and each subgroup stratified by cancer type (T vs C).\
**Notes:** The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamonds represent the summary OR and 95% CI.\
**Abbreviations:** CI, confidence interval; OR, odds ratio; GC, gastric cancer; BC, bladder cancer; M--H, Mantel--Haenszel.](tcrm-11-237Fig2){#f2-tcrm-11-237}

![Forest plots of *PSCA* rs2294008 polymorphism and cancer risk in the overall population and each subgroup stratified by ethnicity (T vs C).\
**Notes:** The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamonds represent the summary OR and 95% CI.\
**Abbreviations:** CI, confidence interval; OR, odds ratio; M--H, Mantel--Haenszel.](tcrm-11-237Fig3){#f3-tcrm-11-237}
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###### 

Characteristics of studies included in the meta-analysis

  Study                              Year   Country                      Ethnicity   Study design   Genotyping method   Source of control   Cancer type   Sample size (case/control)
  ---------------------------------- ------ ---------------------------- ----------- -------------- ------------------- ------------------- ------------- ----------------------------
  Dai et al[@b16-tcrm-11-237]        2014   People's Republic of China   Asian       CC             TaqMan              Population          EC            2,083/2,220
  Wang et al[@b17-tcrm-11-237]       2014   People's Republic of China   Asian       CC             TaqMan              Population          BC            1,210/1,008
  Ma et al[@b18-tcrm-11-237]         2013   People's Republic of China   Asian       CC             iPLEX               Population          BC            184/962
  Zhao et al[@b19-tcrm-11-237]       2013   People's Republic of China   Asian       CC             DHPLC               Population          GC            717/951
  Rizzato et al[@b20-tcrm-11-237]    2013   Venezuela                    Mixed       CC             TaqMan              Hospital            GC            180/1,061
  Rai et al[@b21-tcrm-11-237]        2013   India                        Asian       CC             TaqMan              Population          GBC           405/247
  Ono et al[@b22-tcrm-11-237]        2013   Japan                        Asian       CC             TaqMan              Hospital            GBC           44/173
  Fu et al[@b23-tcrm-11-237]         2012   Europe                       Caucasian   CC             TaqMan              Population          BC            5,393/7,324
  Li et al[@b24-tcrm-11-237]         2012   People's Republic of China   Asian       CC             iPLEX               Hospital            GC            300/300
  Smith et al[@b25-tcrm-11-237]      2012   Scotland                     Caucasian   CC             TaqMan              Hospital            CRC           77/804
  Sala et al[@b26-tcrm-11-237]       2012   Europe                       Caucasian   CC             SNP array           Population          GC            411/1,530
  Zhao et al[@b27-tcrm-11-237]       2012   People's Republic of China   Asian       CC             DHPLC               Population          GC            185/200
  Tanikawa et al[@b28-tcrm-11-237]   2012   Japan                        Asian       CC             SNP array           Hospital            GC            2,300/16,567
  Song et al[@b29-tcrm-11-237]       2011   Korea                        Asian       CC             PCR-RFLP            Hospital            GC            3,245/1,700
  Zeng et al[@b30-tcrm-11-237]       2011   People's Republic of China   Asian       CC             PCR-RFLP            Hospital            GC            460/549
  Lochhead et al[@b31-tcrm-11-237]   2011   Poland                       Caucasian   CC             TaqMan              Population          GC            312/383
  Lochhead et al[@b31-tcrm-11-237]   2011   USA                          Caucasian   CC             TaqMan              Population          Upper GIC     468\*/211
  Wang et al[@b32-tcrm-11-237]       2010   People's Republic of China   Asian       CC             PCR-RFLP            Hospital            BC            581/580
  Ou et al[@b33-tcrm-11-237]         2010   People's Republic of China   Asian       CC             PCR/LDR             Hospital            GC            196/246
  Lu et al[@b34-tcrm-11-237]         2010   People's Republic of China   Asian       CC             PCR-RFLP            Population          GC            1,053/1,100
  Chen et al[@b35-tcrm-11-237]       2010   People's Republic of China   Asian       CC             PCR-RFLP            Hospital            GC            460/549
  Wu et al[@b36-tcrm-11-237]         2009   Europe                       Caucasian   CC             TaqMan              Population          BC            5,038/9,363
  Matsuo et al[@b37-tcrm-11-237]     2009   Japan                        Asian       CC             TaqMan              Hospital            GC            708/708
  Wu et al[@b38-tcrm-11-237]         2009   People's Republic of China   Asian       CC             PCR-RFLP            Population          GC            1,736/1,020
  Sakamoto et al[@b9-tcrm-11-237]    2008   Japan                        Asian       CC             TaqMan              Population          GC            1,531/1,399
  Sakamoto et al[@b9-tcrm-11-237]    2008   Korea                        Asian       CC             TaqMan              Population          GC            871/390

**Notes:**

Including 309 gastric cancer cases and 159 esophageal cancer cases. Lochhead et al[@b31-tcrm-11-237] refers the study evaluated association of the rs2294008 polymorphism with gastric cancer risk and Lochhead et al[@b31-tcrm-11-237] refers to the study evaluated association of the rs2294008 polymorphism with upper GI cancer risk. Sakamoto et al[@b9-tcrm-11-237] refers to the study evaluated association of the rs2294008 with gastric cancer types in Japan and Sakamoto et al[@b9-tcrm-11-237] refers to the study evaluated association of the rs2294008 with gastric cancer types in Korea.

**Abbreviations:** BC, bladder cancer; CC, case--control; CRC, colorectal cancer; DHPLC, denaturing high-performance liquid chromatography; EC, esophageal cancer; GBC, gallbladder cancer; GIC, gastrointestinal cancers; GC, gastric cancer; LDR, ligation detection reaction; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SNP, single nucleotide polymorphism.

###### 

*PSCA* rs2294008 polymorphism genotype distribution and allele frequency in cases and controls

  Study                                  Genotype (N)   Allele frequency (N)   MAF                                                                                
  -------------------------------------- -------------- ---------------------- ------- ------- -------- ------- ------- ------- ------- ------- -------- -------- ------
  **Gastric cancer**                                                                                                                                              
  Zhao et al[@b19-tcrm-11-237]           717            275                    342     100     951      465     401     85      892     542     1,331    571      0.38
  Rizzato et al[@b20-tcrm-11-237]        180            23                     86      69      1,061    231     507     319     132     224     969      1,145    0.63
  Li et al[@b24-tcrm-11-237]             300            124                    141     35      300      168     111     21      389     211     447      153      0.35
  Sala et al[@b26-tcrm-11-237]           411            93                     198     118     1,530    491     714     310     384     434     1,696    1,334    0.53
  Zhao et al[@b27-tcrm-11-237]           185            74                     90      21      200      108     79      13      238     132     295      105      0.37
  Tanikawa et al[@b28-tcrm-11-237]       2,300          1,030                  1,073   197     16,567   6,620   7,587   2,360   3,133   1,467   20,827   12,307   0.32
  Song et al[@b29-tcrm-11-237]           3,245          576                    1,620   1,049   1,700    414     818     468     2,772   3,718   1,646    1,754    0.57
  Zeng et al[@b30-tcrm-11-237]           460            202                    216     42      549      289     223     37      620     300     801      297      0.33
  Lochhead et al I[@b31-tcrm-11-237]     312            47                     143     102     383      101     166     115     237     347     368      396      0.59
  Lochhead et al II[@b31-tcrm-11-237]    309            85                     129     94      211      49      110     49      299     317     208      208      0.51
  Ou et al[@b33-tcrm-11-237]             196            85                     93      18      246      132     96      18      263     129     360      132      0.33
  Lu et al[@b34-tcrm-11-237]             1,053          547                    404     72      1,110    605     387     77      1,498   548     1,597    541      0.27
  Chen et al[@b35-tcrm-11-237]           460            202                    216     42      549      289     223     37      620     300     801      297      0.33
  Matsuo et al[@b37-tcrm-11-237]         708            330                    329     49      708      273     338     97      989     427     884      532      0.30
  Wu et al[@b38-tcrm-11-237]             1,736          759                    819     132     1,020    506     412     77      2,337   1,083   1,424    566      0.32
  Sakamoto et al I[@b9-tcrm-11-237]      1,531          96                     700     728     1,399    210     650     536     892     2,156   1,070    1,722    0.71
  Sakamoto et al II[@b9-tcrm-11-237]     871            133                    461     277     390      122     176     92      727     1,015   420      360      0.58
  **Bladder cancer**                                                                                                                                              
  Wang et al[@b17-tcrm-11-237]           1,210          604                    509     97      1,008    566     376     66      1,717   703     1,508    508      0.29
  Ma et al[@b18-tcrm-11-237]             184            84                     80      11      962      543     355     64      248     102     1,441    483      0.29
  Fu et al[@b23-tcrm-11-237]             5,393          1,363                  2,804   1,226   7,324    2,107   3,645   1,572   5,530   5,256   7,859    6,789    0.49
  Wang et al[@b32-tcrm-11-237]           581            272                    259     50      580      316     220     44      803     359     852      308      0.31
  Wu et al[@b36-tcrm-11-237]             5,038          1,288                  2,613   1,137   9,363    2,842   4,668   1,853   5,189   4,887   10,352   8,374    0.49
  **Other cancers**                                                                                                                                               
  Esophageal cancer                                                                                                                                               
   Dai et al[@b16-tcrm-11-237]           2,083          1,232                  724     127     2,220    1,222   851     147     3,188   978     3,295    1,145    0.23
   Lochhead et al II[@b31-tcrm-11-237]   159            61                     63      34      211      49      110     49      185     131     208      208      0.41
  Gallbladder cancer                                                                                                                                              
   Rai et al[@b21-tcrm-11-237]           405            104                    233     68      247      79      126     42      441     369     284      210      0.46
   Ono et al[@b22-tcrm-11-237]           44             12                     23      9       173      68      75      30      47      41      211      135      0.47
  Colorectal cancer                                                                                                                                               
   Smith et al[@b25-tcrm-11-237]         77             25                     39      13      804      287     387     130     89      65      961      647      0.42

**Notes:** C represents the major allele, T represents the minor allele.

**Abbreviation:** MAF, minor allele frequencies; M--H, Mantel--Haenszel.

###### 

Meta-analysis results

  Comparisons         OR     95% CI       *P*-value   Heterogeneity   Effects model   
  ------------------- ------ ------------ ----------- --------------- --------------- ---
  **T vs C**          1.18   1.08--1.28   0.0001      91%             \<0.00001       R
  Gastric cancer      1.26   1.10--1.45   0.001       94%             \<0.00001       R
  Bladder cancer      1.13   1.06--1.21   0.0005      63%             0.03            R
  Others              0.97   0.81--1.16   **0.75**    62%             0.03            R
  Asian               1.19   1.05--1.35   0.007       93%             \<0.00001       R
  Caucasian           1.15   1.04--1.26   0.004       75%             0.0005          R
  Mixed               1.44   1.14--1.81   0.002       NA              NA              
  **TT vs CC**        1.36   1.14--1.62   0.0008      90%             \<0.00001       R
  Gastric cancer      1.51   1.10--2.08   0.01        94%             \<0.00001       R
  Bladder cancer      1.28   1.20--1.37   \<0.00001   0%              0.57            F
  Others              0.91   0.75--1.10   **0.33**    39%             0.16            F
  Asian               1.37   1.03--1.82   0.03        92%             \<0.00001       R
  Caucasian           1.32   1.10--1.59   0.003       73%             0.001           R
  Mixed               2.17   1.32--3.59   0.002       NA              NA              
  **TC vs CC**        1.29   1.17--1.44   \<0.00001   85%             \<0.00001       R
  Gastric cancer      1.39   1.19--1.63   \<0.0001    87%             \<0.00001       R
  Bladder cancer      1.23   1.17--1.30   \<0.00001   0%              0.65            F
  Others              0.98   0.68--1.41   **0.90**    77%             0.001           R
  Asian               1.36   1.18--1.57   \<0.0001    88%             \<0.00001       R
  Caucasian           1.13   0.95--1.34   **0.16**    79%             \<0.0001        R
  Mixed               1.70   1.05--2.77   0.03        NA              NA              
  **TT + TC vs CC**   1.32   1.18--1.49   \<0.00001   90%             \<0.00001       R
  Gastric cancer      1.44   1.19--1.74   0.0002      92%             \<0.00001       R
  Bladder cancer      1.25   1.19--1.31   \<0.00001   0%              0.64            F
  Others              0.98   0.69--1.38   **0.90**    77%             0.002           R
  Asian               1.38   1.17--1.62   0.0001      92%             \<0.00001       R
  Caucasian           1.18   1.00--1.40   **0.05**    80%             \<0.0001        R
  Mixed               1.88   1.19--2.99   0.007       NA              NA              
  **TT vs CC + TC**   1.15   1.02--1.30   0.02        83%             \<0.00001       R
  Gastric cancer      1.22   0.99--1.49   **0.06**    89%             \<0.00001       R
  Bladder cancer      1.13   1.07--1.20   \<0.0001    0%              0.56            F
  Others              0.95   0.79--1.14   **0.57**    0%              0.96            F
  Asian               1.13   0.93--1.36   **0.87**    87%             \<0.00001       R
  Caucasian           1.15   1.09--1.22   \<0.00001   47%             0.08            F
  Mixed               1.46   1.05--2.03   0.02        NA              NA              

**Note:** *P*-values in bold indicate nonsignificance.

**Abbreviations:** F, fixed; NA, not applicable; R, random; CI, confidence interval; OR, odds ratio; M--H, Mantel--Haenszel.

[^1]: \*These authors contributed equally to this work
